Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 2/20 | 0.35 |
| ▸ | GABRD | O14764 | 2/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL535720 | 1.00 | THRB (0.42) | THRBPOLBGAASLC6A1TSHR | |
| SCHEMBL3934728 | 1.00 | THRB (0.42) | THRBPOLBGAASLC6A1TSHR | |
| SCHEMBL29174145 | 0.93 | POLB (0.42) | THRBPOLBGAASLC6A1TSHR | |
| SCHEMBL51838 | 0.86 | — | — | |
| SCHEMBL3295484 | 0.86 | — | — | |
| SCHEMBL1666449 | 0.86 | — | — | |
| SCHEMBL29883233 | 0.86 | — | — | |
| SCHEMBL8891557 | 0.86 | TRIM24 (0.43) | THRBPOLBGAASLC6A1TSHR | |
| SCHEMBL28501013 | 0.84 | GABRP (0.41) | POLBGAATSHRLMNACYP2C19 | |
| SCHEMBL7893827 | 0.84 | THRB (0.43) | THRBSMN1; SMN2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376085-A1 | BENZIMIDAZOLES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2024-11-14 | — | — | US | disclosed |
| EP-4408530-A1 | BENZIMIDAZOLES AS MODULATORS OF IL-17 | Janssen Pharmaceutica NV (BE) | 2024-08-07 | — | — | EP | disclosed |
| CN-118119613-A | Benzimidazoles as IL-17 modulators | 詹森药业有限公司 | 2024-05-31 | — | — | CN | disclosed |
| WO-2023150568-A2 | ENGINEERED ENONE REDUCTASE AND KETOREDUCTASE VARIANT ENZYMES | CODEXIS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20230242946-A1 | ENGINEERED ENONE REDUCTASE AND KETOREDUCTASE VARIANT ENZYMES | CODEXIS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230242946-A1 | ENGINEERED ENONE REDUCTASE AND KETOREDUCTASE VARIANT ENZYMES | CODEXIS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230167102-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-06-01 | — | — | US | disclosed |
| WO-2023049888-A1 | BENZIMIDAZOLES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-30 | — | — | WO | disclosed |
| US-20220298122-A1 | PROCESS FOR PREPARING CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACID COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2022-09-22 | — | — | US | disclosed |
| WO-2020214545-A1 | PROCESS FOR PREPARING CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACID COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-10-22 | — | — | WO | disclosed |
| US-20180162855-A1 | PDD AND BPD COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2018-06-14 | — | — | US | disclosed |
| EP-3209651-A1 | CARBAZOLE DERIVATIVES | Bristol-Myers Squibb Company (US) | 2017-08-30 | — | — | EP | disclosed |
| US-9096527-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096527-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140171639-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171639-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-8710043-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710043-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130157996-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130157996-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298122-A1 | PROCESS FOR PREPARING CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACID COMPOUNDS | LPAR2, LPAR3, LPAR5 | THRB 1075/4885POLB 2842/4885GAA 744/4885 |
| US-20230167102-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | THRB 1693/4885POLB 3959/4885GAA 586/4885 |
| US-20140171639-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | THRB 1996/4885POLB 4413/4885GAA 1524/4885 |
| US-20130157996-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | THRB 1996/4885POLB 4413/4885GAA 1524/4885 |
| US-20240376085-A1 | BENZIMIDAZOLES AS MODULATORS OF IL-17 | IL17A, IL23R, IL4I1 | THRB 1722/4885POLB 3776/4885GAA 1860/4885 |
| US-20180162855-A1 | PDD AND BPD COMPOUNDS | DRD1, DRD2, XDH | THRB 2686/4885POLB 1531/4885GAA 4363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.